Supplementary Figure S2 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Year: 2025
Type: supplementary-materials
Abstract: Figure S2: Figure 7: Mean ± SD concentration versus time profiles of AR (ADC), total antibody, DM4, and DM4-Me after administration of AR at 2.2 mg/kg IV x 1 plus Bev 10mg/kg IV.
Authors: Husam A. Alqaisi, David E. Cohn, Jing-Yi Chern, Linda R. Duska, Andrea Jewell, Bradley R. Corr, Ira Seth Winer, Eugenia Girda, Marta A. Crispens, Neesha C. Dhani, Ainhoa Madariaga, Robert C. Grant, Matthew Malaguti, Crystal Lee, Valerie Bowering, Horace Wong, Andrew Poothullil, Vanessa Speers, Lisa Wang, Philippe L. Bedard, John C. Brady, Andrew B. Nixon, Li Chen, Claire O’Connor, William Zamboni, Tawyna McKee, Jeffrey A. Moscow, Amit M. Oza, Stephanie Lheureux
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4408535555